Zeng C.,Guanzhou Tumor Hospital in JiangXi Province |
Cai L.,Guanzhou Tumor Hospital in JiangXi Province |
Li J.,Radiation and Interventional Section |
Huang Z.,Guanzhou Tumor Hospital in JiangXi Province |
And 4 more authors.
Chinese Journal of Clinical Oncology
Objective: This study aims to evaluate the influence of Jinlong capsule combined with Transarterial Chemo-embolization (TACE) on the quality of life of patients with primary liver cancer. Methods: A total of 60 cases of patients who met the inclusion criteria were randomly divided into two groups, namely, treatment group (Jinlong Capsule combined with TACE; 30 patients) and control group (treated with TACE only; 30 cases). The patients were administrated with TACE every 30 days as one cycle, and completed at least two cycles. Clinical symptoms, AFP, changes in liver function, adverse reactions, and quality of life evaluation were observed. Results: 1) In the treatment group, the CR had 0 case, PR had 7, SD had 18, and PD had 5 cases, with the control rate (CR+PR+SD) of 83.33%. In the control group, the CR had 0 case, PR had 5, SD had 13, and PD had 12 cases, with the control rate (CR+PR+SD) of 60.00%. The difference between the two groups was statistically significant (P<0.05). 2)The improvement, stable, and deterioration rates of the AFP levels detected in the treatment group were 23.33%, 60.00%, and 16.67%, respectively; whereas those in the control group were 20.00%, 53.33%, and 26.67%, respectively. The difference between the two groups was not statistically significant (P>0.05). 3) The liver function (Child-pugh) rate of improvement and grading control rate in the treatment group were higher than the control group; the differences were statistically significant (P<0.05). 4) The gastrointestinal reactions, leukopenia, hemoglobin, and platelet decline incidence in treatment group is lower than those of the control group; however, the difference was not statistically significant (P>0.05). 5) For the quality of life evaluation, improvement of physical function, psychological function, social function, and the total quality of life of the treatment group was higher than those of the control group; the difference was statistically significant (P<0.05). Conclusion: Jinlong capsule was combined with TACE in the treatment of patients with primary liver cancer. This combination can improve the clinical outcomes, liver function, reduce the TACE drug side effects, and improve the patient quality of life; thus is worthy of clinical application. Source